학술논문
Greater Treatment Satisfaction in Patients Receiving Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) for Relapsed or Refractory Multiple Myeloma (RRMM): COLUMBA
Document Type
ConferencePaper
Author
Source
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 19(10):E247-E248
Subject
Language
English
English
English
ISSN
2152-2650